1 July

Current Opin Cardiol https://journals.lww.com/co-cardiology/

• 07:00
  Editorial introductions Current Opin Cardiol
  No abstract available -- EDITORIAL INTRODUCTIONS
• 07:00
  Electronic health strategies to improve medication adherence in patients with cardiometabolic disease: current status and future directions - Peacock, Erin; Craig, Leslie S.; Krousel-Wood, Marie Current Opin Cardiol
  Purpose of review Enabled by widespread technological advancements, electronic health (eHealth) strategies have expanded rapidly over the last decade, presenting opportunities to support self-management including medication adherence for cardiometabolic disease control. eHealth can minimize (...) -- HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie
• 07:00
  New wrinkles in hypertension management 2022 - Carey, Robert M.; Whelton, Paul K. Current Opin Cardiol
  Purpose of review High blood pressure (BP) is the world's leading risk factor for cardiovascular disease (CVD) and death. This review highlights findings during the past 18 months that apply to the management of high BP in adults in the context of the 2017 American College of (...) -- HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie
• 07:00
  Hypertension and cognitive function: a review of life-course factors and disparities - De Anda-Duran, Ileana; Woltz, Sara G.; Bell, Caryn N.; Bazzano, Lydia A. Current Opin Cardiol
  Purpose of review Dementia is a life-course condition with modifiable risk factors many from cardiovascular (CV) origin, and disproportionally affects some race/ethnic groups and underserved communities in the USA. Hypertension (HTN) is the most common preventable and treatable condition that (...) -- HYPERTENSION: Edited by Hector O. Ventura and Carl J. Lavie
• 07:00
  Editorial: the year in lipids and emerging risk factors - Mukherjee, Debabrata; Mikhailidis, Dimitri P. Current Opin Cardiol
  No abstract available -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  Coronavirus disease 2019 and the cardiologist - Mohammad, Khan O.; Rodriguez, Jose B. Cruz; Urey, Marcus A. Current Opin Cardiol
  Purpose of review There continues to be extensive clinical and epidemiological data to suggest that coronavirus disease 2019 (COVID-19) infection is associated with numerous different types of cardiac involvement. Recent findings Myocardial injury has been reported in over 25% of patients (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  Diet and vascular risk - Gomez-Delgado, Francisco; Romero-Cabrera, Juan Luis; Perez-Martinez, Pablo Current Opin Cardiol
  Purpose of review The basis for the prevention and treatment of cardiovascular disease (CVD) inevitably involves lifestyle modification, including dietary pattern (DP). The aim of this review is to address the different models of healthy DP with their peculiarities and nutritional components as (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity - Mares, Adriana C.; Chatterjee, Saurav; Mukherjee, Debabrata Current Opin Cardiol
  Purpose of review Cardiovascular disease is the most common cause of morbidity and mortality worldwide, and the risk is heightened in the presence of obesity. We review semaglutide, a drug recently approved for chronic weight management in adults with obesity or who are overweight. Recent (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  N-3 polyunsaturated fatty acids for cardiovascular risk - Goff, Zackary D.; Nissen, Steven E. Current Opin Cardiol
  Purpose of review Use of omega-3 fatty acid (OM3FA) supplements to reduce risk of cardiovascular events has been investigated, largely without evidence of meaningful benefit, over the last 4 decades. Recent findings The first contemporary clinical trial to show benefit of OM3FA use was the (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  RNA interference-based therapies for the control of atherosclerosis risk factors - Kettunen, Sanna; Ruotsalainen, Anna-Kaisa; Ylä-Herttuala, Seppo Current Opin Cardiol
  Purpose of review Atherosclerosis, characterized by lipid accumulation and chronic inflammation in the arterial wall, is the leading causes of death worldwide. The purpose of this article is to review the status of RNA interference (RNAi) based therapies in clinical trials for the treatment and (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  Update on cancer therapy-induced atherosclerosis - Reeves, David J.; Rao, Vijay U. Current Opin Cardiol
  Purpose of review Recent advances in oncologic therapies have significantly improved overall survival for patients with malignancy. However, cardiovascular complications have not only increased in this population due to shared risk factors and pathophysiology, but also due to the therapies (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee
• 07:00
  What cardiologists should know about cardiac sarcoidosis in 2022? - Lemay, Sylvain; Marchand, Laurie; Sénéchal, Mario Current Opin Cardiol
  Purpose of review Cardiac sarcoidosis (CS) is a potentially fatal condition when unrecognized or not treated adequately. The purpose of this review is to provide new strategies to increase clinical recognition of CS and to present an updated overview of the immunosuppressive treatments using (...) -- LIPIDS AND EMERGING RISK FACTORS: Edited by Dimitri P. Mikhailidis and Debabrata Mukherjee